Starting Treatment

Get Started on VPRIV

In order to begin treatment with VPRIV, you should work with your physician to complete, sign and submit a Start Form, available for download.

pink callout button

If you have questions about the form, please contact us

Details About VPRIV

Read more about type 1 Gaucher disease management with VPRIV.

VPRIV has been proven to be an effective treatment option for patients with type 1 Gaucher disease.

LEARN MORE

OnePath® Services

Learn about the many support services that OnePath® can offer you

onepath

OnePath® is a comprehensive and personalized support program for eligible patients, families, and healthcare providers needing assistance with approved Shire Human Genetic Therapies, Inc. products.

LEARN MORE

Reimbursement and Insurance Support Services

Important Materials to Get You Started With Treatment

If you have type 1 Gaucher disease and are starting treatment with VPRIV, we’ve prepared several useful materials that may be helpful to you. Many of the questions you may have can be answered by referring to the following downloadable PDF documents:

Introducing OnePath®
Highlights important OnePath® services, including the OnePath® Access Program.

Benefits of the OnePath® Co-pay Assistance Program
Explains the OnePath® Co-pay Assistance Program if you need assistance paying for out-of-pocket medication costs.

Getting the Coverage You Need at 65
A great resource that provides information on insurance coverage you’ll need when you turn 65 years of age.

OnePath® Start Form
A form you’ll initially complete to get enrolled in OnePath®

onepath

If you have any questions or concerns or need more information about product support services, please call OnePath® at 1-866-888-0660.

VPRIV is available by prescription only.

Indication

VPRIV is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for pediatric and adult patients with type 1 Gaucher disease.

Important Safety Information

  • The most serious side effects seen in patients in clinical trials with VPRIV were allergic reactions. Patients who have experienced allergic reactions to VPRIV or to other enzyme replacement therapy should proceed with caution.
  • The most common side effects observed in clinical trials in patients treated with VPRIV were infusion-related and included: headache, dizziness, low blood pressure, high blood pressure, nausea, weakness/fatigue, and fever. Generally, infusion-related reactions were mild and, in newly treated patients, occurred mostly during the first 6 months of treatment and tended to occur less frequently with time.
  • Management of infusion-related reactions is based on severity and may include slowing the infusion rate, treatment with medications such as antihistamines, fever-reducing agents and/or corticosteroids, and/or stopping and resuming treatment with increased infusion time. Side effects and any treatment concerns should be discussed with your physician.
  • The most commonly reported side effects (occurring in ≥10% of patients) that were considered related to VPRIV included: headache, dizziness, abdominal pain, nausea, back pain, joint pain, upper respiratory tract infection, aPTT prolonged (eg, blood clotting difficulty), infusion-related reactions, fever, and weakness/fatigue.
  • All adult side effects of VPRIV are considered relevant to children (ages 4 to 17 years). Side effects more commonly seen in children compared with adult patients included: upper respiratory tract infection, rash, aPTT prolonged, and fever. The safety of VPRIV has not been established in patients younger than 4 years of age.
  • As with all therapeutic proteins, there is the potential of developing antibodies. It is unknown if the presence of antibodies to VPRIV is associated with a higher risk of infusion reactions. Patients with an immune response to other enzyme replacement therapies who are switching to VPRIV should continue to be monitored for antibodies.
  • Your doctor may prescribe VPRIV to you if you are pregnant, only if it is clearly necessary.
  • Tell your healthcare provider if you experience any side effects. For more information about VPRIV, ask your healthcare provider, read the Full Prescribing Information, visit www.VPRIV.com, or call Shire at 1-866-888-0660.
  • You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.